Search Results - "CANDELORO, Giampiero"

Immunotherapy in Patients with Less than Complete Response to Chemotherapy by RECCHIA, Francesco, CANDELORO, Giampiero, NECOZIONE, Stefano, BISEGNA, Roberta, BRATTA, Massimo, REA, Silvio

“…Background: Patients with metastatic solid tumors (MST) with less than a complete response to chemotherapy (L-CR), a depressed immune system and elevated serum…”
Get full text

Prolonged Disease Control after Myeloablative Chemotherapy, Autologous Transplantation and Immunotherapy in High-risk Early Breast Cancer by RECCHIA, Francesco, CANDELORO, Giampiero, NECOZIONE, Stefano, ACCORSI, Patrizia, RECCHIA, Cornelia Ortensia Carla, TOMBOLINI, Vincenzo, REA, Silvio

“…Background: Failure to eradicate all cancer stem cells, lymphocytopenia, and high levels of vascular endothelial growth factor (VEGF) may explain the limited…”
Get full text

Dose-finding Study of Docetaxel Added to Ifosfamide and Cisplatin Followed by Concomitant Capecitabine and Radiotherapy in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck by RECCHIA, Francesco, SAGGIO, Gaetano, CESTA, Alisia, AMICONI, Giovanna, DI BLASIO, Anna, CANDELORO, Giampiero, VALERIANI, Maurizio, TOMBOLINI, Vincenzo, REA, Silvio

“…Background: Docetaxel (DOC) is a promising new drug in the management of squamous cell carcinoma of the head and neck. The aim of this phase I study was to…”
Get full text

Maintenance immunotherapy in stage IV cancer patients who have a clinical benefit from chemotherapy by Recchia, Francesco, Candeloro, Giampiero, Rea, Silvio

“…Abstract only 3021 Background: Even if patients with stage IV cancer (AC) may have prolonged remissions with chemotherapy (CT), the majority of them, will…”
Get full text

Paclitaxel Plus Gemcitabine in Advanced Non-small Cell Lung Cancer Patients with Low Performance Status by RECCHIA, Francesco, SAGGIO, Gaetano, CESTA, Alisia, CANDELORO, Giampiero, REA, Silvio

“…Background: The aim was to determine the efficacy and safety of a platinum-free regimen combining gemcitabine and paclitaxel for the treatment of patients with…”
Get full text

Abstract CT109: Adjuvant ovarian suppression in high risk premenopausal breast cancer: ten-year follow-up of a phase I-II study by Recchia, Francesco, Candeloro, Giampiero, Bratta, Massimo, Rosselli, Michele, Rea, Silvio

“…Abstract Background: Two randomized studies have shown the benefit of ovarian suppression in the adjuvant treatment of high risk premenopausal breast cancer,…”
Get full text

Maintenance immunotherapy in patients with advanced cancer (AC): Long term follow-up of a phase II study by Recchia, Francesco, Candeloro, Giampiero, Necozione, Stefano, Bratta, Massimo, Rosselli, Michele, Rea, Silvio

“…Abstract only…”
Get full text

Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer by Recchia, Francesco, Candeloro, Giampiero, Rosselli, Michele, Bratta, Massimo, Pasta, Vittorio, D'Orazi, Valerio, Fumagalli, Luca A, Rea, Silvio

“…Premenopausal patients with breast cancer and more than 10 positive axillary nodes (BC>10) have a poor prognosis: In these patients the best adjuvant therapy…”
Get full text

Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin-eluting beads compared with lipiodol by RECCHIA, Francesco, PASSALACQUA, Giovanni, FILAURI, Pietro, DODDI, Marco, BOSCARATO, Pietro, CANDELORO, Giampiero, NECOZIONE, Stefano, DESIDERI, Giovambattista, REA, Silvio

“…Chemoembolization with lipiodol (TACE) improves survival of selected patients with unresectable hepatocellular carcinoma (HCC), but results in substantial…”
Get full text

Abstract CT301: Late disease recurrence in estrogen receptor positive (ER+) premenopausal breast cancer (BC) by Recchia, Francesco, Candeloro, Giampiero, Necozione, Stefano, Rea, Silvio, Hoo, William Soo, Cantor, Tom

“…Abstract Background: BC is often a slowly growing disease. For this reason, in order to establish the validity of a therapeutic approach, we need long term…”
Get full text

Abstract 5366: Extended phase II study of maintenance immunotherapy in advanced cancer by Recchia, Francesco, Candeloro, Giampiero, Desideri, Giovambattista, Necozione, Stefano, Rea, Silvio

“…Abstract Purpose: Chemotherapy can induce prolonged remissions in patients with stage IV cancer (AC), yet nearly the majority of them, will ultimately relapse…”
Get full text

Gonadotropin‐releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma by Recchia, Francesco, Saggio, Gaetano, Amiconi, Giovanna, Blasio, Anna Di, Cesta, Alisia, Candeloro, Giampiero, Rea, Silvio

“…BACKGROUND The objective of the current study was a retrospective evaluation of 100 consecutive premenopausal women with high‐risk, early breast carcinoma who…”
Get full text

Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes by Giotta, Francesco, Acito, Luigi, Candeloro, Giampiero, Del Medico, Pietro, Gadaleta‐Caldarola, Gennaro, Giordano, Guido, Gueli, Rossana, Lugini, Antonio, Magri, Valentina, Mandarà, Marta, Masci, Giovanna, Pisconti, Salvatore, Pistelli, Mirco, Rizzi, Anna, Salesi, Nello, Schirone, Alessio, Scognamiglio, Giovanni, Tedeschi, Maria, Zucchinelli, Patrizia

“…Background. Evidence on the management and treatment of male breast cancer is scant. We report the analysis of a multicenter Italian series of patients with…”
Get full text

Total estrogen blockade and chemotherapy in high-risk premenopausal early breast cancer (BC): Long-term follow-up of a phase II study by Recchia, Francesco, Candeloro, Giampiero, Cesta, Alisia, Necozione, Stefano, Rea, Silvio, Bratta, Massimo, Soo Hoo, William, Cantor, Thomas

“…Abstract only…”
Get full text

Maintenance immunotherapy in recurrent ovarian cancer: Long term follow-up of a phase II study by Recchia, Francesco, Di Orio, Ferdinando, Candeloro, Giampiero, Guerriero, Gabriele, Piazze, Juan, Rea, Silvio

“…Abstract Objectives Vascular endothelial growth factor (VEGF), a mediator of tumor-associated immunodeficiency, plays a key role in angiogenesis and is a…”
Get full text

Abstract 5055: The role of estrogens and vascular endothelial growth factor (VEGF) in premenopausal breast cancer carginogenesis and disease progression by Recchia, Francesco, Candeloro, Giampiero, Desideri, Giovambattista, Necozione, Stefano, Rea, Silvio

“…Abstract Background. Estrogen is important in breast cancer development and there is evidence in vitro, that it modulates VEGF expression in breast cancer…”
Get full text

A multicenter, open-label phase II trial of liposomal doxorubicin (LD) and docetaxel (DX), followed by concurrent chemotherapy and radiation therapy in locally advanced high-risk, early breast cancer (HRBC) by Recchia, Francesco, Candeloro, Giampiero, Cesta, Alisia, Desideri, Giovambattista, Necozione, Stefano, Rea, Silvio

“…Abstract only e11041 Background: Taxanes and anthracyclines (ANs) are among the most active agents in the treatment of breast cancer. However, ANs are…”
Get full text

Abstract 480: Maintenance immunotherapy following carboplatin (CBDCA) - pemetrexed (PEM) chemotherapy in advanced adenocarcinoma (ADK) of the lung: A phase II study by Recchia, Francesco, Candeloro, Giampiero, Cesta, Alisia, Di Blasio, Anna, Recchia, Cornelia O.C., Necozione, Stefano, Desideri, Giovambattista, Rea, Silvio

“…Abstract Background: Continuation maintenance therapy with PEM vs. placebo has been shown to improve progression-free survival (PFS) and overall survival (OS),…”
Get full text

Beta-interferon, retinoids and tamoxifen in metastatic breast cancer : Long-term follow-up of a phase II study by RECCHIA, Francesco, SICA, Gigliola, CANDELORO, Giampiero, NECOZIONE, Stefano, BISEGNA, Roberta, BRATTA, Massimo, REA, Silvio

“…Based on a series of in vitro data, including the additive and/or synergistic antiproliferative effect of interferon and tamoxifen on breast cancer cell lines,…”
Get full text

Abstract 3722: Ovarian suppression with gonadotropin-releasing hormone analogues (Gn-RH) in high risk premenopausal breast cancer patients (PM-HR-BC): decrease of T regulatory cells (T-regs) and of vascular endothelial growth factor (VEGF) by Recchia, Francesco, Candeloro, Giampiero, Necozione, Stefano, Desideri, Giovambattista, D'Andrea, Maurizio S., Recchia, Cornelia O.C., Rea, Silvio

“…Abstract Background: In a previous phase II study we have shown an improvement of disease-free survival and overall survival of 180 premenopauseal high-risk…”
Get full text